Can Kovina Therapeutics turn HPV16 E6 from an undruggable viral protein into a cancer target?
See how Kovina Therapeutics’ HPV16 E6 inhibitors restore p53 in preclinical models and what must happen before human trials.
Pharma & Biotech
Pharma & Biotech
Proton therapy delivers survival gain in head and neck cancer: Could this Lancet trial shift payer and policy resistance?
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the